AbbVie Reports Second-Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
AbbVie (ABBV) Shares Fall 6% Following Revenue Miss
July 29, 2022 12:04 PM EDTAbbVie (NYSE: ABBV) shares tumbled 6% Friday following its earnings report before the open, which beat earnings estimates but missed revenue expectations.
The biopharmaceutical company posted earnings per share of $3.37, $0.03 above expectations of $3.34, with revenue missing the consensus estimate of $14.67 billion, coming in at $14.58 billion. However, revenue did increase 4.5%... More
AbbVie (ABBV) Tops Q2 EPS by 3c, Maintains FY EPS Guidance
July 29, 2022 7:42 AM EDTAbbVie (NYSE: ABBV) reported Q2 EPS of $3.37, $0.03 better than the analyst estimate of $3.34. Revenue for the quarter came in at $14.58 billion versus the consensus estimate of $14.67 billion.
GUIDANCE:
AbbVie sees FY2022 EPS of $13.78-$13.98, versus the consensus of... More
